Glioblastoma (GBM) is the most common primary adult brain tumor. Even with surgery, standard chemotherapy, and radiation, tumor recurrence and patient relapse are inevitable with a median survival rate of

The Centre for the Commercialization of Antibodies and Biologics (CCAB) is working with Empirica Therapeutics (Empirica), a Canadian start-up company focused on developing data-driven treatments for cancer, to address the unmet medical needs of glioblastoma (GBM), the most common adult malignant primary brain tumor. Current therapies are only partly effective, with frequent relapse and poor […]

Long dsRNA is produced by viruses during their replicative cycle. In plants and invertebrates, long dsRNAs block crucial cellular processes through RNA interference (RNAi). In vertebrates, long dsRNA is a potent inducer of critical signaling proteins that regulate antiviral immune responses. Although the RNAi system is conserved in vertebrates, there is little evidence to suggest […]

Glioblastoma (GBM), the most common and deadly form of primary brain cancer in adults. After diagnosis, GBM patients undergo standard therapy, including surgery, chemotherapy and radiation therapy. Unfortunately, disease relapse is inevitable and patients face a median survival of less than 15 months. A small population of tumor cells, known as brain tumor initiating cells […]

Antibodies are the fastest growing segment of the pharmaceutical market, and with modern engineering technologies antibodies can be programmed to target devastating diseases. Within the immune system, antibodies fight invading bacteria and viruses. High-quality synthetic antibodies directed to disease-related targets have immense therapeutic potential. Development of cell-based assays to enable rapid identification of functionally active […]

In human viral diseases, misbehaviour of the cellular machinery utilizing ubiquitin is frequently observed. Ubiquitin is a small protein that attaches to target proteins in human cells and signals for their destruction. Human deubiquitinases are enzymes that remove ubiquitin to keep protein levels in balance. Viral pathogens have evolved proteins that mimic human deubiquitinases to […]

Cancer is a devastating disease defined by genetic changes that result in the activation of proteins that encourage cell growth or prevent cell death. Modern oncology aims to specifically target these tumour-promoting proteins, which has the secondary benefit of leaving normal cells unharmed, unlike chemotherapy. Recently, a number of drugs that specifically block tumour-promoting proteins […]

Glioblastoma (GBM) is the most common primary adult brain tumor, characterized by extensive cellular and genetic heterogeneity. Even with surgery, standard chemotherapy, and radiation, tumor recurrence and patient relapse are inevitable with a median survival rate of

In human viral diseases, misbehaviour of the cellular machinery utilizing ubiquitin is frequently observed. Ubiquitin is a small protein that attaches to target proteins in human cells and signals for their destruction. Human deubiquitinases are enzymes that remove ubiquitin to keep protein levels in balance. Viral pathogens have evolved proteins that mimic human deubiquitinases to […]